JP2014530842A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530842A5
JP2014530842A5 JP2014536290A JP2014536290A JP2014530842A5 JP 2014530842 A5 JP2014530842 A5 JP 2014530842A5 JP 2014536290 A JP2014536290 A JP 2014536290A JP 2014536290 A JP2014536290 A JP 2014536290A JP 2014530842 A5 JP2014530842 A5 JP 2014530842A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
group
transthyretin
pharmaceutically acceptable
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014536290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530842A (ja
JP6068484B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/070945 external-priority patent/WO2013060668A1/en
Publication of JP2014530842A publication Critical patent/JP2014530842A/ja
Publication of JP2014530842A5 publication Critical patent/JP2014530842A5/ja
Application granted granted Critical
Publication of JP6068484B2 publication Critical patent/JP6068484B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014536290A 2011-10-24 2012-10-23 トランスサイレチン関連アミロイドーシスの新規療法 Active JP6068484B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382326 2011-10-24
EP11382326.4 2011-10-24
PCT/EP2012/070945 WO2013060668A1 (en) 2011-10-24 2012-10-23 New therapy for transthyretin-associated amyloidosis

Publications (3)

Publication Number Publication Date
JP2014530842A JP2014530842A (ja) 2014-11-20
JP2014530842A5 true JP2014530842A5 (https=) 2015-12-10
JP6068484B2 JP6068484B2 (ja) 2017-01-25

Family

ID=47076222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014536290A Active JP6068484B2 (ja) 2011-10-24 2012-10-23 トランスサイレチン関連アミロイドーシスの新規療法

Country Status (19)

Country Link
US (5) US9610270B2 (https=)
EP (1) EP2770988B1 (https=)
JP (1) JP6068484B2 (https=)
KR (1) KR102017354B1 (https=)
CN (1) CN103889407B (https=)
AU (2) AU2012327275B2 (https=)
BR (1) BR112014009322B1 (https=)
CA (1) CA2852808C (https=)
CL (1) CL2014000893A1 (https=)
CY (1) CY1118151T1 (https=)
ES (1) ES2593038T3 (https=)
IL (1) IL231907B (https=)
MX (2) MX385516B (https=)
PL (1) PL2770988T3 (https=)
PT (1) PT2770988T (https=)
RU (2) RU2747536C2 (https=)
SG (2) SG11201401215VA (https=)
WO (1) WO2013060668A1 (https=)
ZA (1) ZA201402546B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2747536C2 (ru) * 2011-10-24 2021-05-06 Сом Инновэйшн Биотек, С.Л. Новая терапия транстиретин-ассоциированного амилоидоза
DK3185957T3 (da) * 2014-08-29 2022-08-29 Alnylam Pharmaceuticals Inc Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
EP3275433A1 (en) 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
US20210008209A1 (en) * 2018-03-12 2021-01-14 Corino Therapeutics, Inc. Combination therapy for ttr amyloidosis
EP3976017A4 (en) * 2019-05-31 2023-06-14 Plex Pharmaceuticals, Inc. PHARMACOLOGICAL SUBSTANCES FOR THE TREATMENT OF PROTEIN AGGREGATION DISEASES OF THE EYE
JP2023549533A (ja) * 2020-11-13 2023-11-27 プレックス ファーマスーティカルズ,インク 眼の状態を処置するための薬理剤
CN114324693B (zh) * 2022-01-14 2023-01-13 大连博源医学科技有限公司 一种血液中转甲状腺素蛋白(ttr)四聚体浓度测定的预处理方法和检测方法
WO2024081554A2 (en) * 2022-10-10 2024-04-18 Corino Therapeutics, Inc. Modified release tolcapone formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
WO1998027972A2 (en) 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
PT1372682E (pt) 2001-03-15 2012-08-03 Proteotech Inc Catequinas para o tratamento de fibrilogénese em doença de alzheimer, doença de parkinson, amiloidose αa sistémica e outras perturbações amiloides
WO2004065614A2 (en) 2002-01-29 2004-08-05 Protemix Corporation Limited Suppression of cytotoxic protein conformers
US20040175382A1 (en) 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
AU2005215136A1 (en) 2004-02-20 2005-09-01 Novartis Ag DPP-IV inhibitors for treating neurodegeneration and cognitive disorders
CN1921856A (zh) * 2004-02-20 2007-02-28 诺瓦提斯公司 用于治疗神经变性疾病和认知障碍的dpp-iv抑制剂
KR20070032700A (ko) * 2004-05-20 2007-03-22 폴드알엑스 파마슈티칼스, 인크. 트랜스티레틴을 안정화하고 트랜스티레틴 미스폴딩을억제하기 위한, 2-((헤테로)아릴)-벤즈옥사졸 화합물 및유도체, 그리고 조성물 및 방법
WO2006026555A2 (en) 2004-08-30 2006-03-09 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
GB2429645A (en) 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
US20120016037A1 (en) 2006-07-24 2012-01-19 Frank Toppo Method for prevention and treatment of Alzheimers
GB0718718D0 (en) 2007-09-25 2007-11-07 Pentraxin Therapeutics Ltd Compound and use thereof
DE102010010572A1 (de) 2010-03-08 2011-09-08 Mahle International Gmbh Trockenseparator
RU2747536C2 (ru) * 2011-10-24 2021-05-06 Сом Инновэйшн Биотек, С.Л. Новая терапия транстиретин-ассоциированного амилоидоза

Similar Documents

Publication Publication Date Title
JP2014530842A5 (https=)
JP2019517587A5 (https=)
JP2018534348A5 (https=)
JP2009514874A5 (https=)
JP2018536641A5 (https=)
RU2014114930A (ru) Новая терапия транстиретин-ассоциированного амилоидоза
JP2016510317A5 (https=)
JP2014511892A5 (https=)
JP2015511638A5 (https=)
JP2012193216A5 (https=)
AR048431A1 (es) Formulaciones galenicas de compuestos organicos
RU2013121788A (ru) Ингибиторы репликации вич
JP2013542261A5 (https=)
JP2006504795A5 (https=)
AR094374A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos
JP2008543854A5 (https=)
JP2008503533A5 (https=)
JP2013531031A5 (https=)
JP2016534063A5 (https=)
JP2011505347A5 (https=)
JP2017508817A5 (https=)
JP2012502047A5 (https=)
JP2011088926A5 (https=)
JP2009517411A5 (https=)
AR029412A1 (es) Forma cristalina